Nurse Practitioner Program year 2025 Reported 2021–2025 Source: CMS Open Payments, 2026 publication

Lisa Harvey

Nurse Practitioner, Adult Health Hot Springs, AR Nurse Practitioner

NPI 1962409334 CMS profile 10990570

4419 N Highway 7, Hot Springs, AR 71909

Open in the dashboard

General payments

$7,621

526 records reported · program years 2021–2025

Research payments

$0

Paid to them · None reported · program years 2021–2025

Ownership & investment interest

$0

None reported

Through program year 2025, Lisa Harvey of Hot Springs, AR is reported in the CMS Open Payments database as having received $7,621 across 526 general payments and $0 in research payments paid to them.

No combined total General, research and ownership are kept apart. Each is reported under its own rules, and ownership is not money that moved at all but the value of a stake held. A meal, a clinical trial grant and a shareholding do not add up to anything meaningful, so this site does not add them.

General payments for this record sit in the 95th percentile of Nurse Practitioner, Adult Health profiles with reported payments. Percentile describes the distribution, not the conduct.

By program year

5 rows
Year Kind Relative to this record's peak year Amount Records
2025 General $1,800 125
2024 General $1,251 95
2023 General $1,542 103
2022 General $1,710 114
2021 General $1,319 89

Beside peers

Year by year, beside peers General payments · among profiles paid that year
  • Lisa Harvey
  • Nurse Practitioner, Adult Health median
  • Middle half of Nurse Practitioner, Adult Health
  • National median

In program year 2025, general payments to Lisa Harvey were reported at $1,800. Among 12,696 Nurse Practitioner, Adult Health profiles paid that year, the median was $184 and the middle half received between $59 and $580.

Show as a table
Year Lisa Harvey Nurse Practitioner, Adult Health median Middle half National median
2019 $0 — — $163
2020 $0 — — $114
2021 $1,319 $138 $43–$438 $132
2022 $1,710 $165 $54–$494 $149
2023 $1,542 $178 $61–$549 $160
2024 $1,251 $186 $62–$575 $164
2025 $1,800 $184 $59–$580 $169

Breakdown

Who paid General payments · program years 2021–2025
  1. AbbVie, Inc. $1,531 157 payments
  2. AstraZeneca Pharmaceuticals LP $1,041 56 payments
  3. Abbott Laboratories $589 27 payments
  4. Lilly USA, LLC $524 42 payments
  5. Novo Nordisk Inc $382 27 payments
  6. Dexcom, Inc. $304 18 payments
  7. Pfizer Inc. $281 21 payments
  8. GlaxoSmithKline, LLC. $277 19 payments
  9. Salix Pharmaceuticals, a division of Bausch Health US, LLC $247 13 payments
  10. ITI, Inc. $227 13 payments
  11. Other $2,219 133 payments

Every payment, record by record

What the payments were for General payments · program years 2021–2025
  1. Food and Beverage $7,621 526 payments
Products named General payments · program years 2021–2025
  1. FARXIGA $664 34 payments
  2. VRAYLAR $645 56 payments
  3. UBRELVY $624 69 payments
  4. QULIPTA $438 44 payments
  5. FreeStyle Libre 3 $394 18 payments
  6. MOUNJARO $368 30 payments
  7. BREZTRI $313 10 payments
  8. AIRSUPRA $305 17 payments
  9. TRELEGY ELLIPTA $277 19 payments
  10. ZENPEP $271 15 payments
  11. Other $5,404 350 payments

A payment can name more than one product, so these amounts overlap and do not add up to the general-payment figure.

Prescribing to Medicare patients

Part D · data year 2024 · 107 drugs

Part D claims

4,598

Median for Nurse Practitioner: 389

Drug cost

$285,218

Median for Nurse Practitioner: $21,885

Branded share of claims

16.6%

Median for Nurse Practitioner: 19.6%

Drugs this doctor was counted under in Medicare Part D 2024, by drug cost
Drug Type Relative to their largest Claims Drug cost
Ozempic Semaglutide Brand 25 $44,188
Mounjaro Tirzepatide Brand 23 $37,100
Xarelto Rivaroxaban Brand 27 $27,638
Farxiga Dapagliflozin Propanediol Brand 26 $27,207
Trelegy Ellipta Fluticasone/Umeclidin/Vilanter Brand 35 $24,646
Eliquis Apixaban Brand 18 $23,767
Januvia Sitagliptin Phosphate Brand 15 $23,676
Tresiba Flextouch U-100 Insulin Degludec Brand 12 $6,776
Basaglar Kwikpen U-100 Insulin Glargine,hum.Rec.Anlog Brand 16 $5,069
Pitavastatin Calcium Generic 25 $5,008

The 10 drugs with the highest cost, of 107 counted.

Drug cost is what was paid for the drugs at the pharmacy — by Medicare, the patient and others — and is not money to the prescriber. Medicare Part D only: drugs dispensed to Medicare beneficiaries. A drug with fewer than 11 claims for this prescriber is not published, so a missing drug does not mean zero. The medians are for the 229,976 Part D prescribers listed as Nurse Practitioner; they describe a distribution and say nothing about conduct.

Billing to Medicare

Part B · data year 2024 · 85 billing codes

Paid by Medicare

$30,887

Of which drugs: $2,362

Medicare patients

165

Average age 73

Services billed

1,899

95 women, 70 men among their patients

Share of this provider's Medicare patients with each condition
Condition among their Medicare patients Relative to the most common Share of patients
High blood pressure 70%
Arthritis 46%
Ischemic heart disease 28%
Diabetes 22%
Depression 17%
Chronic kidney disease 15%
Osteoporosis 15%
Atrial fibrillation 13%
Drugs given in the clinic that this provider billed Medicare Part B for
Drug given in the clinic Where Patients Services Paid by Medicare
Injection, triamcinolone acetonide, not otherwise specified, 10 mg J3301 Office 15 60 $31
Injection, dexamethasone sodium phosphate, 1 mg J1100 Office 15 144 $9

Medicare Part B only: services billed to Medicare. Rows covering fewer than 11 beneficiaries are not published. Only drugs given in the clinic are itemised here; the rest of what this provider billed is in the total above.

Payments and prescribing

First 5 of 21 products · payments 2024

Two separate records. The payments come from Open Payments and the claims from Medicare. They are set side by side because they name the same product; they do not show that a payment affected a prescription.

Products this doctor was paid in connection with in 2024, beside Medicare claims for the same product
Product Paid by Related payments Part D claims Part B services
VRAYLAR
  • AbbVie, Inc. $161
$161 — —
AIRSUPRA
  • AstraZeneca Pharmaceuticals LP $143
$143 — —
Auvelity
  • Axsome Therapeutics, Inc. $115
$115 — —
UBRELVY
  • AbbVie, Inc. $101
$101 — —
MOUNJARO
  • Lilly USA, LLC $93
$93 23 —

A dash means Medicare published no figure for this doctor and product — fewer than 11 claims, or the product is not covered under that part — which is not the same as none. Payments are general payments only; one that names several products is split evenly between them, so an amount is payments related to the product, not money paid for it.

See all 21 in the dashboard with a free account

Records

526 reported

Every payment, record by record

Date, company, amount, what it was for and the product named — filter by year, kind and company, or download as CSV.

Other Nurse Practitioner, Adult Health in Arkansas

Related records

What this means

U.S. law requires drug and medical device manufacturers to report payments and transfers of value they make to physicians and teaching hospitals. The Centers for Medicare & Medicaid Services publishes that record each year. This page shows what was reported about this person, and nothing else.

An ownership interest is different from the other two. It is not a payment: it is a stake — shares, options, a partnership holding — that a physician or an immediate family member held in a manufacturer during that year. The figure shown is what the stake was reported to be worth.

Research payments frequently pass through a clinician to the institution running a trial, and rarely represent personal income. They should be read differently from general payments.

Provenance

Source: CMS Open Payments · through program year 2025

Data current to program year 2025, from CMS's 2026 publication.

We reproduce what manufacturers reported. We do not verify, edit or correct the underlying records.

A payment record is not evidence of wrongdoing. Financial relationships between industry and medicine are legal, common and often necessary for research. Who Paid My Doc reports what was disclosed; it does not judge it.

Who Paid My Doc is independent and is not affiliated with, endorsed by or sponsored by CMS or any U.S. government agency. It is not a consumer reporting agency and this is not a consumer report; do not use it for decisions covered by the Fair Credit Reporting Act.

How to dispute or correct a record